Case Studies
Portage Glasgow Limited
Disruptyx Therapeutics
Developing the next-generation of precision peptide therapeutics against cancer
The University of Glasgow uses cookies for analytics and advertising. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar helps us to understand and improve our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Developing the next-generation of precision peptide therapeutics against cancer